2021年9月13日:
返回五月，桑德斯，埃斯拉塔托特和埃斯塔利斯的供应商申请从药品的福利计划（PBS）中申请劳动这些药物，因为它们在财务上不可行。与澳大利亚皇家妇产科和新西兰学院合作的AMS与澳大利亚的内分泌学会（ESA）写信给部长狩猎，表示我们对埃斯特拉多和埃斯塔利斯的担忧以及如果这些药物有关的潜在健康结果从PBS中退出。
Following further discussions, Sandoz agreed to apply to the Pharmaceutical Benefits Advisory Committee (PBAC) for a price increase instead of delisting Estradot and Estalis from the PBS. Again, in collaboration with RANZCOG and ESA, AMS wrote a joint letter of support to PBAC for a price increase, rather than them being delisted from the PBS.
AMS is now happy to advise that the PBAC has agreed to the price increase for Estradot and Estalis from 1 October. This price increase means that these medications will remain on the PBS and support continuous and sustainable supply to the Australian market. While many women will need to pay more for these medications from 1 October, importantly, women on a healthcare card will only need to pay the concession price. A letter from Sandoz is attached for further information.
For the past few months, people have been feeling the impacts of COVID-19 on their daily lives.
